Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation

Abstract

We aimed to investigate the frequency, risk factors, and outcome of active tuberculosis (TB) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This retrospective, nested, case-control study reviewed data from 6236 patients who received allo-HSCT from January 2008 to December 2018 at a single center; thirty-three patients (0.5%) with active TB and 99 controls without active TB after allo-HSCT were identified. We performed propensity score matching by randomly selecting 3 controls for each identified active TB patient according to the time of transplantation and follow-up period. History of pretransplant active TB previously treated and inactive at time of transplantation (P< .001) was an independent risk factor. No significant differences in overall survival (P= .342), nonrelapse mortality (P= .497), or incidence of relapse (P= .807) were found. Thirty (90.9%) patients were treated with 4-drug (isoniazid, rifampicin/three rifapentine, pyrazinamide, and ethambutol) or 3-drug combination first-line therapy, with a response rate of 76.7%. Twenty-six (78.8%) patients were treated with first-line and second-line combined therapy, and the response rate was 76.9%. Five (15.2%) patients developed hepatotoxicity. In conclusion, history of pretransplant active TB previously treated and inactive at time of transplantation was an independent risk factor of active TB after allo-HSCT. No significant differences in prognosis between the TB and control groups were found. More studies are needed to help develop standardized therapeutic strategies for patients with post-transplant TB.

Next-Generation Metagenome Sequencing Shows Superior Diagnostic Performance in Acid-Fast Staining Sputum Smear-Negative Pulmonary Tuberculosis and Non-tuberculous Mycobacterial Pulmonary Disease

“…Additionally, it has been reported that patients with impaired immune function and structural lung disease are more susceptible to fungal and other microbial infections after PTB and NTM-PD (Wu and Holland, 2015;Zeng et al, 2020). Specifically, when an immune-impaired host has a mixed infection of pulmonary infiltration, the successful diagnosis of co-existing opportunistic infections using conventional diagnostic methods is challenging (Pan et al, 2019).…”

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies

“…The allo-HSCT cells are collected from normal donors without tumor cell contamination and have an antitumor immunological effect due to the low relapse rate and high disease-free survival (DFS). However, under allo-HSCT treatment, patients should take immunosuppressants for long periods of time to avoid immunologic rejection, which may cause diverse infections, such as bacteria, viruses, fungi, and protozoan [ 4 ].…”

Infecção latente por Mycobacterium tuberculosis em transplante de células tronco hematopoiéticas

“…Foram analisados 33 indivíduos com diagnóstico de TB em atividade e 99 sem TB (grupo controle). História de TB prévia foi um fator de risco independente, não foram observadas diferenças em relação a sobrevida geral, mortalidade e reincidência de doença de base (59).…”